GENE ONLINE|News &
Labcorp Acquires BioReference Health’s Oncology Testing Division for $192 Million
Labcorp has announced the acquisition of BioReference Health’s cancer testing business in a deal valued at $192 million. The transaction involves the oncology-focused division of BioReference Health, which is owned by Opko Health. This move comes as Opko Health continues efforts to streamline operations and reduce expenses in pursuit of profitability.
BioReference Health, known for its diagnostic services, has been undergoing cost-cutting measures under its parent company, Opko Health. The sale of its oncology testing segment marks a strategic shift for the company as it seeks financial stability. Labcorp, a global leader in laboratory diagnostics and testing services, will integrate this new acquisition into its portfolio to expand its capabilities in cancer diagnostics.
Date: March, 2025
Newsflash | Powered by GeneOnline AI
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
